Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric Cancer

HER2 Positive Gastric Cancer Clinical Trial

Official title:
A Phase I Study of Pyrotinib In Combination With Docetaxel In Patients With HER2 Positive Advanced Gastric Cancer

Status Recruiting

Clinical Trial Summary

Pyrotinib is an oral tyrosine kinase inhibitor targeting both EGFR and HER-2 receptors. This study is designed to evaluate the safety and tolerability of Pyrotinib or Pyrotinib in combination with Docetaxel in patients with HER2 positive advanced gastric cancer.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02378389
Study type	Interventional
Source	Jiangsu HengRui Medicine Co., Ltd.
Contact	Qing Yang, MD
Phone	157 0515 5017
Email	yangqing@hrs.com.cn
Status	Recruiting
Phase	Phase 1
Start date	September 2014
Completion date	August 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03409848` - Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma	Phase 2
Completed	`NCT03602079` - Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene	Phase 1/Phase 2
Completed	`NCT03319459` - FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors	Phase 1
Not yet recruiting	`NCT05165602` - Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System
Active, not recruiting	`NCT04727151` - TAC T-cells for the Treatment of HER2-positive Solid Tumors	Phase 1/Phase 2